Revisiting the public health implications of the United States–Mexico– Canada agreement

This commentary re-examines a recent article by Labonté et al on the recent changes to two relevant provisions relating to patent rights in the final version of the United-States-Mexico-Canada Agreement (USMCA). Although the USMCA’s final revised version does not add more pharmaceutical patent prote...

Descripción completa

Detalles Bibliográficos
Autor principal: Adekola, Tolulope Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275535/
https://www.ncbi.nlm.nih.gov/pubmed/32503571
http://dx.doi.org/10.1186/s12992-020-00579-y
_version_ 1783542805226848256
author Adekola, Tolulope Anthony
author_facet Adekola, Tolulope Anthony
author_sort Adekola, Tolulope Anthony
collection PubMed
description This commentary re-examines a recent article by Labonté et al on the recent changes to two relevant provisions relating to patent rights in the final version of the United-States-Mexico-Canada Agreement (USMCA). Although the USMCA’s final revised version does not add more pharmaceutical patent protection than those that already exist in the three trading partners, the agreement has done little to enhance access to generic medicines and biosimilars.
format Online
Article
Text
id pubmed-7275535
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72755352020-06-08 Revisiting the public health implications of the United States–Mexico– Canada agreement Adekola, Tolulope Anthony Global Health Letter to the Editor This commentary re-examines a recent article by Labonté et al on the recent changes to two relevant provisions relating to patent rights in the final version of the United-States-Mexico-Canada Agreement (USMCA). Although the USMCA’s final revised version does not add more pharmaceutical patent protection than those that already exist in the three trading partners, the agreement has done little to enhance access to generic medicines and biosimilars. BioMed Central 2020-06-05 /pmc/articles/PMC7275535/ /pubmed/32503571 http://dx.doi.org/10.1186/s12992-020-00579-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter to the Editor
Adekola, Tolulope Anthony
Revisiting the public health implications of the United States–Mexico– Canada agreement
title Revisiting the public health implications of the United States–Mexico– Canada agreement
title_full Revisiting the public health implications of the United States–Mexico– Canada agreement
title_fullStr Revisiting the public health implications of the United States–Mexico– Canada agreement
title_full_unstemmed Revisiting the public health implications of the United States–Mexico– Canada agreement
title_short Revisiting the public health implications of the United States–Mexico– Canada agreement
title_sort revisiting the public health implications of the united states–mexico– canada agreement
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275535/
https://www.ncbi.nlm.nih.gov/pubmed/32503571
http://dx.doi.org/10.1186/s12992-020-00579-y
work_keys_str_mv AT adekolatolulopeanthony revisitingthepublichealthimplicationsoftheunitedstatesmexicocanadaagreement

Ejemplares similares